Organigram Global (OGI) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Organigram Global (OGI) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 51.0% versus a loss of 67.6%. Over five years, OGI leads with a -89.4% price change compared with -100.0% for TNXP. Organigram Global is the larger company by market cap ($135.7 million vs $126.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OGI | TNXP |
|---|---|---|
| Share price | $0.9412 | $7.35 |
| Market cap | $135.68M | $126.06M |
| 1-day change | -1.04% | +0.96% |
| YTD return | -43.39% | -53.39% |
| 1-year return | -50.97% | -67.63% |
| 5-year return | -89.39% | -100.00% |
| P/E ratio (TTM) | 2.19 | — |
| Forward P/E | 39.22 | — |
| EPS (TTM) | $0.43 | $-13.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.24 | $22.38 |
| 52-week low | $0.853 | $7.10 |
| Distance from 52-week high | -57.98% | -67.16% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | — | +505.44% |
| Average volume | 884.72K | 542.97K |
| Shares outstanding | 144.15M | 17.15M |
| Employees | 1,139 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OGI has outperformed TNXP by 16.7 percentage points over the past year.
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
OGI vs TNXP FAQ
Which is bigger, Organigram Global or Tonix Pharmaceuticals?
Organigram Global (OGI) is larger, with a market capitalization of $135.68M compared with $126.06M for Tonix Pharmaceuticals (TNXP).
Which stock has performed better over the past year, OGI or TNXP?
OGI returned -50.97% over the past 12 months, compared with -67.63% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are Organigram Global and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.